Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05127174 Recruiting - Clinical trials for Myeloproliferative Neoplasm

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Start date: March 14, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).

NCT ID: NCT05125523 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

Start date: December 28, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to estimate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Sirolimus for Injection (Albumin Bound) in patients with solid malignancies.

NCT ID: NCT05123365 Recruiting - Myelofibrosis Clinical Trials

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Start date: January 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).

NCT ID: NCT05122572 Recruiting - Clinical trials for Advanced Solid Tumor

RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Start date: November 1, 2021
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-lable study to determine the safety, tolerability and preliminary efficacy of oncolytic virus injection (RT-01) combined with or without immune checkpoint inhibitors (Nivolumab) in the treatment of patients with advanced solid tumors.

NCT ID: NCT05120518 Recruiting - Pediatric Cancer Clinical Trials

Post Mortem Tissue Donation of Pediatric Tumor Tissues and Cells

Start date: August 14, 2019
Phase:
Study type: Observational

The objective of this study is to utilize all donated pediatric tumor tissues and cells obtained from autopsy to prospectively develop novel patient derived orthotopic xenograft (PDOX) mouse models as well as in vitro cell culture model systems for pediatric cancers, and also provide tissue samples to other researchers and organizations (eg, CBTN, DIPG Registry, COG).

NCT ID: NCT05119933 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Start date: November 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, multicenter study designed to evaluate the maximum tolerated, safety, tolerability and PK of oral YY-15293 in patients with advanced solid tumors with a KRAS G12C mutation, to confirm the recommended phase 2 dose of YY-15293, and to obtain preliminary efficacy information in patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.

NCT ID: NCT05119907 Recruiting - Solid Tumor Clinical Trials

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Start date: October 12, 2021
Phase: Phase 2
Study type: Interventional

The goal of this study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with solid tumor.

NCT ID: NCT05119335 Recruiting - Clinical trials for Renal Cell Carcinoma

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Start date: October 26, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.

NCT ID: NCT05118841 Recruiting - Clinical trials for Advanced Solid Tumor

Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors

Start date: January 3, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1, first-in-human, open-label, multicenter, dose escalation and dose expansion study to investigate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of ZX-4081 administered orally (PO) twice daily (BID) in 28-day cycles in patients with Advanced Solid Tumors.

NCT ID: NCT05118789 Recruiting - Clinical trials for Metastatic Solid Tumor

A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Start date: January 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-520 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-520 in patients with advanced ROS1-positive NSCLC and other solid tumors.